METHOD OF TREATING HEPATOCELLULAR CARCINOMA

1 . A method of treating, or delaying the onset of, hepatocellular carcinoma, comprising administering to a patient in need of treatment an effective amount of a compound that is trans-[tetrachlorobis(1H-indazole)ruthenate(III)] or a pharmaceutically acceptable salt thereof.

2 . The method of claim 1 , wherein the compound is an alkali metal salt of trans-[tetrachlorobis(1H-indazole)ruthenate(III)].

3 . The method of claim 1 , wherein the compound is sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)].

4 . The method of claim 1 , wherein the hepatocellular carcinoma is a refractory or recurrent hepatocellular carcinoma.

5 . The method of claim 4 , wherein the hepatocellular carcinoma is refractory or resistant to one or more agents chosen from the group consisting of sorafenib, regorafenib, anthracyclines, platinum agents, 5-FU or capecitabine.

6 . The method of claim 4 , wherein the hepatocellular carcinoma is refractory or resistant to sorafenib.

7 . The method of claim 4 , wherein the hepatocellular carcinoma is refractory or resistant to doxorubicin.

8 . The method of claim 4 , wherein the hepatocellular carcinoma is refractory or resistant to oxaliplatin or cisplatin.

9 . The method of claim 4 , wherein the hepatocellular carcinoma is refractory or resistant to 5-FU.

10 . The method of claim 1 , further comprising administering to the patient an effective amount of an embolizing agent.

11 . A method of treating hepatocellular carcinoma, comprising:

identifying a patient having hepatocellular carcinoma; and

treating the patient with a therapeutically effective amount of a pharmaceutically acceptable salt of trans-[tetrachlorobis(1H-indazole)ruthenate(III)].

12 . A kit comprising a unit dosage form of a pharmaceutically acceptable salt of trans-[terachlorobis(1H-indazole)ruthenate(III)] and a unit dosage form of an embolizing agent.